Pan-cancer analysis and experimental validation revealed the m6A methyltransferase KIAA1429 as a potential biomarker for diagnosis, prognosis, and immunotherapy
Figure 2.Differential expression of KIAA1429 at mRNA and protein levels in normal and tumor tissues.